The results were most striking for patients who received treatments soon after becoming sick, when their viral loads were still low—death rates dropped to 11 pe

The results were most striking for patients who received treatments soon after becoming sick, when their viral loads were still low—death rates dropped to 11 percent with mAb114 and just 6 percent with Regeneron’s drug, compared with 24 percent with ZMapp and 33 percent with Remdesivir.